АНТИАГРЕГАНТЫ В ПЕРВИЧНОЙ ПРОФИЛАКТИКЕ СЕРДЕЧНО-СОСУДИСТЫХ ЗАБОЛЕВАНИЙ И ПРОФИЛАКТИКЕ АТЕРОТРОМБОЗА У БОЛЬНЫХ СО СТАБИЛЬНОЙ ФОРМОЙ ИШЕМИЧЕСКОЙ БОЛЕЗНИ СЕРДЦА: АСПЕКТЫ ЭФФЕКТИВНОСТИ И БЕЗОПАСНОСТИ

Обзор посвящен применению антиагрегантов. Рассматриваются патогенез артериального тромбоза, механизмы действия антиагрегантов и рекомендации по применению препаратов этого класса для первичной профилактики сердечно-сосудистых заболеваний и предупреждения атеротромботических осложнений стабильной ишемической болезни сердца. Приводятся сведения о механизмах развития и причинах резистентности к антиагрегантам. Обсуждаются проблема безопасности антиагрегантной терапии, способы снижения риска кровотечений и предотвращения гастропатии, индуцированной ацетилсалициловой кислотой.

атеротромбоз, антиагреганты, ацетилсалициловая кислота, кровотечения, гастропатия, atherothrombosis, antiaggregants, acetylsalicylic acid, bleeding, gastropathy

1. Banerjee A. Aspirin and Salicylates. Dialogues in Cardiovascular Medicine 2002;7 (1):44-47.

2. Cyrus T., Sung S., Zhao L. et al. Effect of low-dose aspirin on vascular inflammation, plaque stability, and atherogenesis in low-density lipoprotein receptor-deficient mice. Circulation 2002;106:1282-1287.

3. Cattaneo M. ADP receptors antagonists. In: Platelets. Ed. Michelson A. D. San Diego: Academic Press 2006:1127-1144.

4. Farid N. A., Smith R. L., Gillespie T. A. et al. The disposition of prasugrel, a novel thienopiridine, in humans. Drug Metab Dispos 2007;35:1096-1104.

5. Husted S., van Giezen J.J. Ticagrelor: the first reversibly binding oral P2Y12 receptor antagonist. Cardiovasc Ther 2009;27 (4):259-274.

6. Cattaneo M. New P2Y12 inhibitors. Circulation 2010;121:171-179.

7. Armstrong P. C., Peter K. GpIIb /IIIa inhibitors: From bench to bedside and back to bench again. Thromb Haemost 2012;107:808-814.

8. Shah R. Protease-activated receptors in cardiovascular health and diseases. Am Heart J 2009;157:253-262.

9. Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med 1989;321:129-135.

10. Peto R., Gray R., Collins R. et al. Randomised trial of prophylactic daily aspirin in British male doctors. Br Med J 1988;296:313-316.

11. e Medical Research Council's General Practice Research Framework. ^rombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. Lancet 1998;351:233-241.

12. Hansson L., Zanchetti A., Carruthers S. G. et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998;351:1755-1762.

13. Primary Prevention Project Investigators Low dose aspirin and vitamin E in people at cardiovascular risk: a randomized trial in general practice. Collaborative Group of the Primary Prevention Project (PPP). Lancet 2001;357:89-95.

14. Ridker P. M., Cook N. R., Lee I. M. et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005;352:1293-1304.

15. Hart R. G., Halperin J. L., McBride R. et al. Aspirin for the primary prevention of stroke and other major vascular events. Meta-analysis and hypotheses. Arch Neurol 2000;57:326-332.

16. Sunmuganathan P. S., Ghahramani P., Jackson P. R. et al. Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomized trials. Heart 2001;85:265-271.

17. Antithrombotic Trialists' Collaboration, Baigent C., Blackwell L., Collins R. et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009;373:1849-1860.

18. Ogawa H., Nakayama M., Morimoto T. et al. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA 2008;300:2134-2141.

19. Fowkes F. G., Price J. F., Stewart M. C. et al. Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial. JAMA 2010;303:841-848.

20. Belch J., MacCuish A., Campbell I. et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial. BMJ 2008;337: a1840.

21. Bartolucci A. A., Tendera M., Howard G. Metaanalysis of multiple primary prevention trials of cardiovascular events using aspirin. Am J Cardiol 2011;107:1796-1801.

22. Raju N., Sobieraj-Teague M., Hirsh J. et al. Effect of aspirin on mortality in the primary prevention of cardiovascular disease. Am J Med 2011;124:621-629.

23. Berger J. S., Lala A., Krantz M.J. et al. Aspirin for the prevention of cardiovascular events in patients without clinical cardiovascular disease: a metaanalysis of randomized trials. Am Heart J 2011;162:115-124, e2. 20-23.

24. Sarwar N., Gao P., Seshasai S. R. et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative metaanalysis of 102 prospective studies. Lancet 2010;375:2215-2231.

25. Pignone M., Alberts M.J., Colwell J. A. et al. Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation. Circulation 2010;121:2694-2701.

26. Collaborative overview of randomised trials of antiplatelet therapy-I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. BMJ 1994;308:81-106.

27. Antithrombotic Trialists' Collaboration Collaborative meta-analysis of randomised trials of antiplatelet therapy for the prevention of death, myocardial infarction and stroke in high risk patients. BMJ 2002;324:71-86.

28. De Berardis G., Sacco M., Strippoli G. F. et al. Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials. BMJ 2009;339: b4531-4538.

29. Saito Y., Okada S., Ogawa H. et al. Low-dose aspirin for primary prevention of cardiovascular events in patients with Type 2 diabetes mellitus: 10-year follow-up of a randomized controlled trial Circulation 2017;135:659-670.

30. Vandvik P. O., Lincoff A. M., Gore J. M. et al. Primary and secondary prevention of cardiovascular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th edition: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141: e637S-668S.

31. Bibbins-Domingo K. U. S. Preventive Services Task Force. Aspirin use for the primary prevention of cardiovascular disease and colorectal cancer: U. S. Preventive Services Task Force recommendation statement. Ann Intern Med 2016; doi:10.7326/M16-0577.

32. Piepoli M. F., Hoes A. W., Agewall S. et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 2016;37:2315-2381.

33. Bhatt D. L., Fox K. A., Hacke W. et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006;354:1706-1717.

34. Cook N. R., Lee I. M., Gaziano J. M. et al. Low-Dose Aspirin in the Primary Prevention of Cancer: the Women's Health Study: a Randomised Controlled Trial. JAMA 2005; 294 (1):47-55.

35. Cook N. R., Lee I. M., Zhang S. M. et al. Alternateday, low-dose aspirin and cancer risk: long-term observational follow-up of a randomized trial. Ann Intern Med 2013;159:77-85.

36. Rothwell P. M., Price J. F., Fowkes F. G. et al. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet 2012;379:1602-1612.

37. Mills E.J., Wu P., Alberton M. et al. Low-dose aspirin and cancer mortality: a meta-analysis of randomized trials. Am J Med 2012;125:560-567.

38. Rothwell P. M., Fowkes F. G., Belch J. F. et al. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet 2011;377:31-41.

39. Flossman E., Rothwell P. M. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet 2007;369:1603-1613.

40. Juul-Moller S., Edvardsson N., Jahnmatz B. et al. Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris: The Swedish Angina Pectoris Aspirin Trial (SAPAT) Group. Lancet 1992;340 (8833):1421-1425.

41. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348:1329-1339.

42. Schmit K., Dolor R.J., Jones W. S. et al. Comparative effectiveness review of antiplatelet agents in peripheral artery disease. J Am Heart Assoc 2014;3: e001330.

43. Belch J.J., DormandyJ., Biasi G. M. et al. Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial. J Vasc Surg 2010;52:825-833.

44. Aboyans V., Ricco J-B., Bartelink M-L. E. L. et al. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS) Eur Heart J 2017;00:1-60 doi:10.1093/eurheartj/ehx095.

45. Sacco R. L., Diener H. C., Yusuf S. et al. Aspirin and extended release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med 2008;359:1238-1251.

46. Hiatt W. R., Fowkes F. G. R., Heizer G. et al. Ticagrelor versus clopidogrel in symptomatic peripheral artery disease. N Engl J Med 2017;376:32-40.

47. Johnston S. C., Amarenco P., Albers G. W. et al. Ticagrelor versus aspirin in acute stroke or transient ischemic attack. N Engl J Med 2016;375:35-43.

48. Bhatt D. L., Flather M. D., Hacke W. et al. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol 2007;49:1982-1988.

49. Morrow D. A., Braunwald E., Bonaca M. P. et al. Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med 2012; 366: 1404-1413.

50. Montalescot G., Sechtem U., Achenbach S. et al. 2013 ESC guidelines on the management of stable coronary artery disease: The Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J 2013;34:2949-3003.

51. Windecker S., Kolh P., Alfonso F. et al. 2014 ESC/EACTS Guidelines on myocardial revascularisation. The Task Force on Myocardial Revascularisation of the European Society of Cardiology (ESC) and European Association of Cardio-^oracic Surgery. Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 2014;35:2541-2619.

52. Valgimigli M., Bueno H., Byrne R. A. et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. Eur Heart J 2017;0:1-48. doi:10.1093/eurheartj / ehx419.

53. Schomig A., Neumann F. J., Kastrati A. et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 1996;334:1084-1089.

54. Bertrand M. E., Legrand V., Boland J. et al. Randomized multicenter comparison ofconventional anticoagulation versus antiplatelet therapy in unplanned and electivecoronary stenting. Circulation 1998;98:1597-1603.

55. Bangalore S., Kumar S., Fusaro M. et al. Short- and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117762 patient-years of follow-up from randomized trials. Circulation 2012;125:2873-2891.

56. Schulz-Schupke S., Byrne R. A., Ten Berg J. M. et al. ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 vs. 12 months of clopidogrel therapy after drug-eluting stenting. Eur Heart J 2015;36:1252-1263.

57. Feres F., Costa R. A., Abizaid A. et al. OPTIMIZE Trial investigators. ^ree vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial. JAMA 2013;310:2510-2522.

58. Urban P., Meredith I. T., Abizaid A. et al. for the LEADERS FREE Investigators. Polymer-free Drug-Coated Coronary Stents in Patients at High Bleeding Risk. N Engl J Med 2015;373:2038-2047.

59. Kirchhof P., Benussi S., Kotecha D. et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016;37:2893-2962.

60. Nieuwlaat R., Capucci A., Camm A.J. et al. on behalf of the Euro Heart Survey Investigators Atrial fibrillation management: a prospective survey in ESC Member Countries ^e Euro Heart Survey on Atrial Fibrillation Eur Heart J 2005;26;2422-2434.

61. Hart R. G., Pearce L. A, Aguilar M. I. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007;146:857-867.

62. ACTIVE Investigators, Connolly S. J, Pogue J., Hart R. G. et al. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med 2009;360 (20):2066-2078.

63. Connolly S.J., Eikelboom J., Joyner C. et al. Apixaban in patients with atrial fibrillation, N Engl J Med 2011;364:806-817.

64. Leon M. B., Baim D. S., Popma J.J. et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med 1998;339:1665-1671.

65. ACTIVE Writing Group of the ACTIVE Investigators. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 2006;367:1903-1912.

66. Gibson M., Mehran R., Bode Ch. et al. Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI. N Engl J Med 2016;375:2423-2434.

67. Cannon P. Ch., Bhatt D. L., Oldgren J. et al. for the RE-DUAL PCI Steering Committee and Investigatorson. Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation N Engl J Med 2017;377:1513-1524.

68. Eikelboom J. W., Connolly S. J., Bosch J. Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. N Engl J Med; DOI:10.1056/NEJMoa1709118.

69. Wang T. H., Bhatt D. L., Topol E. J. Aspirin and clopidogrel resistance: an emerging clinical entity Eur. Heart J 2006;27:647-654.

70. Michelson A. D., Cattaneo M., Eikelboom J. W. et al. Aspirin Resistance: Position Paper of the Working Group on Aspirin Resistance, Platelet Physiology Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost 2005;3:1-3.

71. Gurbel P. A., Tantry U. S. Clopidogrel resistance? Thrombosis Res 2007;120:311-321.

72. Collet J.-P., Hulot J.-S., Pena A. et al. Cytochrome P4502C12 polymorphism in young patients treated clopidogrel after myocardial infarction: a cohort study. Lancet 2009;373:309-317.

73. Sibbing D., Stegherr J., Latz W. et al. Cytochrome P4502C19 loss of-function polymorphism and stent thrombosis following percutaneous coronary intervention. Eur Heart J 2009;30:916-922.

74. Paré G., Mehta S. R., Yusuf S. et al. Effects of CYP2C19 Genotipe on Outcomes of Clopidogrel Treatment. N Engl J Med 2010;363:1704-1714.

75. Frelinger A. L. III, Bhatt D. L., Lee R. D. et al. Clopidogrel pharmacokinetics and pharmacodynamics vary widely despite exclusion or control of polymorphisms (CYP2C19, ABCB1, PON1), noncompliance, diet, smoking, co-medications (including proton pump inhibitors), and pre-existent variability in platelet function. J Am Coll Cardiol 2013; January 9.

76. Holmes M. V., Perel P., Shah T. et al. CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis. JAMA 2011;306 (24):2704-2714.

77. Storey R. F., Husted S., Harrington R. A. et al. Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antago nist, compared with clopidogrel in patients with acute coronary syndromes. J Am Coll Cardiol 2007;50 (19):1852-1856.

78. Gurbel P. A., Bilden K. P., Butler K. et al. Randomized Double-Blind Assessment of the ONSET and OFFSET of the Antiplatelet Effects of Ticagrelor Versus Clopidogrel in Patients With Stable Coronary Artery Disease. ^e ONSET/OFFSET Study. Circulation 2009;120:2577-2585.

79. Mehran R., Baber U., Steg P. G. et al. Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study. Lancet 2013;382:1714-1722.

80. Biondi-Zoccai G. G. L., Lotrionte M, Agostoni P. et al. A systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50279 patients at risk for coronary artery disease. Eur Heart J 2006;27:2667-2674.

81. Patrono C., Garcia Rodriguez L. A., Landolfi R., Baigent C. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med 2005;353:2373-2383.

82. Kelly J. P., Kaufman D. W., Jurgelon J. M. et al. Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product. Lancet 1996;348:1413-1416.

83. Tarnawski A., Stachura J., Gergely H., Hollander D. Gastric micro-vascular endothelium: a major target for aspirin-induced injury and arachidonic acid protection. An ultrastructural analysis in the rat. Eur J Clin Invest 1990;20:432-440.

84. Hawthorne A. B., Mahida Y. R., Cole A. T., Hawkey C.J. Aspirin-induced gastric mucosal damage: prevention by enteric-coating and relation to prostaglandin synthesis. Br J Clin Pharmacol 1991;32:77-83.

85. Dietz R., Rauch B. Leitline zur Diagnose und Behandlung der chronischen koronarien Herzerkrankung der Deutschen Gesellschaft für Kardiologie. Herz- und Kreislaufforschung (DGK). Z Kardiol 2003;92:501-521.